ClinicalTrials.gg
CompletedNCT02255500Updated Mar 8, 2021Results posted

EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty

A Phase 4 interventional study of Bupivacaine FNB and EXPAREL Infiltration in Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-08.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 146 studies testing bupivacaine in Pain — 19 open to participants now, 19 under way, 3 of them phase 3. Bupivacaine · Pain.

Enrollment
118th of 146
23 · median 63
Started
2014
with 19 others
Phase 4
55 of 146
6 open now
Registered
55th of 146
by date
Lead sponsor
16 of 146
Pacira Pharmaceuticals, Inc

Among the 146 studies testing bupivacaine in Pain, this one is the 118th largest by enrollment, is one of 20 that started in 2014, is one of 55 in phase 4, and was the 55th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

19 of the 146 studies testing bupivacaine in Pain are open now, in 5 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies testing bupivacaine in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and pharmacokinetics of EXPAREL in subjects who undergo femoral nerve block with bupivacaine HCl for unilateral total knee arthroplasty (TKA).

Read the detailed description

On Day 1, eligible subjects will receive a single 20 mL dose of bupivacaine hydrochloride (HCl) 0.5% with epinephrine 1:200,000 within 2 hours prior to the surgical procedure as an ultrasound-guided femoral nerve block (FNB). EXPAREL 266 mg expanded to 60 mL with preservative-free sterile normal saline will be infiltrated into the surgical site prior to wound closure. There will be no local coadministration of the two drugs.

Blood samples for bupivacaine pharmacokinetic (PK) analysis will be obtained from subjects at baseline (prior to bupivacaine HCl administration for nerve block), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours after the beginning of EXPAREL administration, and on Day 14.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Total knee arthroplasty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females ≥18 years of age.
  2. (ASA) physical status 1, 2, or 3.
  3. Scheduled to undergo femoral nerve block in conjunction with unilateral TKA.
  4. Female subjects must be surgically sterile, at least 2 years , or using a medically acceptable method of . Females of must have a documented negative blood or urine pregnancy test result within 24 hours before surgery.
  5. Able to provide , adhere to the study schedule, and complete all study assessments.

Exclusion criteria

Exclusion Criteria:

  1. History of or idiosyncratic reactions to amide-type local anesthetics or opioids.
  2. to bupivacaine.
  3. Received bupivacaine or any other local anesthetic within 7 days of EXPAREL administration.
  4. Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after EXPAREL administration.
  5. Planned concurrent surgical procedure (e.g., bilateral TKA).
  6. Body weight \<50 kg (110 pounds) or a ≥45 kg/m2.
  7. Received any drug within 30 days prior to EXPAREL administration, and/or has planned administration of another investigational product or procedure during the subject's participation in this study.
  8. Previous participation in an EXPAREL study.
  9. in the last 2 years, with the exception of non- basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  10. Current or historical evidence of any disease or condition, especially cardiovascular or neurological conditions that, in the opinion of the Investigator, may increase the risk of surgery or complicate the subject's postsurgical course.
  11. Clinically significant medical or psychiatric disease that, in the opinion of the Investigator, would constitute a contraindication to participation in the study, or cause inability to comply with the study requirements.

    In addition, the subject will be ineligible to receive EXPAREL if he or she meets the following criteria during surgery:

  12. Any clinically significant event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that might render the subject medically unstable or complicate the subject's postsurgical course.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Bupivacaine FNB + EXPAREL Infiltration

    Femoral nerve block with bupivacaine HCl 0.5% with epinephrine 1:200,000 within 2 hours of the surgical procedure. Infiltration of EXPAREL 266 mg just prior to wound closure.

    Drug: Bupivacaine FNB · Drug: EXPAREL Infiltration

Interventions

  • A single administration of bupivacaine HCl 0.5% with epinephrine 1:200,000 in 20 mL volume will be administered within 2 hours prior to the surgical procedure as an ultrasound-guided FNB.

    Also known as: Bupivacaine

  • A single dose of EXPAREL 266 mg expanded to 60 mL with preservative-free sterile normal saline will be infiltrated into the surgical site just prior to wound closure.

    Also known as: Liposomal bupivacaine

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    The maximum observed plasma concentration of a drug in the body after the drug has been administered. Blood samples for bupivacaine pharmacokinetic (PK) analysis were to be obtained from subjects at baseline (prior to bupivacaine HCl administration for nerve block), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days after the beginning of EXPAREL administration

    Time frame: Baseline, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days post-dose

  2. Time to Peak Plasma Concentration (Tmax)

    The time to reach the maximum observed plasma concentration (Cmax) Blood samples for bupivacaine PK analysis were to be obtained from subjects at baseline (prior to bupivacaine HCl administration for nerve block), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days after the beginning of EXPAREL administration

    Time frame: Baseline, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days post-dose

  3. Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration After Drug Administration (AUC0-last)

    Total drug exposure up to the last measurable concentration Blood samples for bupivacaine PK analysis were to be obtained from subjects at baseline (prior to bupivacaine HCl administration for nerve block), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days after the beginning of EXPAREL administration

    Time frame: Baseline, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days post-dose

  4. Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity After Drug Administration (AUC0-∞)

    Total drug exposure, extrapolated to infinity Blood samples for bupivacaine PK analysis were to be obtained from subjects at baseline (prior to bupivacaine HCl administration for nerve block), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days after the beginning of EXPAREL administration

    Time frame: Baseline, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days post-dose

  5. The Apparent Terminal Elimination Rate Constant (λz)

    Blood samples for bupivacaine PK analysis were to be obtained from subjects at baseline (prior to bupivacaine HCl administration for nerve block), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days after the beginning of EXPAREL administration

    Time frame: Baseline, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days post-dose

  6. The Apparent Terminal Elimination Half-life (t1/2el)

    Blood samples for bupivacaine PK analysis were to be obtained from subjects at baseline (prior to bupivacaine HCl administration for nerve block), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days after the beginning of EXPAREL administration

    Time frame: Baseline, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days post-dose

07

Results

Posted Nov 24, 2020

Participant flow

Participant flow — Overall Study
MilestoneBupivacaine FNB + EXPAREL InfiltrationBupivacaine FNB + EXPAREL Infiltration Admixed With Bupivacaine
Started167
Completed157
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax)

The maximum observed plasma concentration of a drug in the body after the drug has been administered. Blood samples for bupivacaine pharmacokinetic (PK) analysis were to be obtained from subjects at baseline (prior to bupivacaine HCl administration for nerve block), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days after the beginning of EXPAREL administration

Time frame:
Baseline, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days post-dose
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax)
ng/mLBupivacaine FNB + EXPAREL InfiltrationBupivacaine FNB + EXPAREL Infiltration Admixed With Bupivacaine
Maximum Plasma Concentration (Cmax)499 ± 148775 ± 299
PrimaryTime to Peak Plasma Concentration (Tmax)

The time to reach the maximum observed plasma concentration (Cmax) Blood samples for bupivacaine PK analysis were to be obtained from subjects at baseline (prior to bupivacaine HCl administration for nerve block), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days after the beginning of EXPAREL administration

Time frame:
Baseline, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days post-dose
Reported as:
Median · hours
Time to Peak Plasma Concentration (Tmax)
hoursBupivacaine FNB + EXPAREL InfiltrationBupivacaine FNB + EXPAREL Infiltration Admixed With Bupivacaine
Time to Peak Plasma Concentration (Tmax)0.675 (0.183 to 78.0)47.450 (0.183 to 72.9)
PrimaryArea Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration After Drug Administration (AUC0-last)

Total drug exposure up to the last measurable concentration Blood samples for bupivacaine PK analysis were to be obtained from subjects at baseline (prior to bupivacaine HCl administration for nerve block), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days after the beginning of EXPAREL administration

Time frame:
Baseline, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days post-dose
Reported as:
Mean · hours*ng/mL
Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration After Drug Administration (AUC0-last)
hours*ng/mLBupivacaine FNB + EXPAREL InfiltrationBupivacaine FNB + EXPAREL Infiltration Admixed With Bupivacaine
Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration After Drug Administration (AUC0-last)28234 ± 1071046600 ± 16489
PrimaryArea Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity After Drug Administration (AUC0-∞)

Total drug exposure, extrapolated to infinity Blood samples for bupivacaine PK analysis were to be obtained from subjects at baseline (prior to bupivacaine HCl administration for nerve block), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days after the beginning of EXPAREL administration

Time frame:
Baseline, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days post-dose
Reported as:
Mean · hours*ng/mL
Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity After Drug Administration (AUC0-∞)
hours*ng/mLBupivacaine FNB + EXPAREL InfiltrationBupivacaine FNB + EXPAREL Infiltration Admixed With Bupivacaine
Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity After Drug Administration (AUC0-∞)25134 ± 1150638489 ± NA
PrimaryThe Apparent Terminal Elimination Rate Constant (λz)

Blood samples for bupivacaine PK analysis were to be obtained from subjects at baseline (prior to bupivacaine HCl administration for nerve block), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days after the beginning of EXPAREL administration

Time frame:
Baseline, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days post-dose
Reported as:
Mean · 1/hours
The Apparent Terminal Elimination Rate Constant (λz)
1/hoursBupivacaine FNB + EXPAREL InfiltrationBupivacaine FNB + EXPAREL Infiltration Admixed With Bupivacaine
The Apparent Terminal Elimination Rate Constant (λz)0.0290 ± 0.0089.0315 ± NA
PrimaryThe Apparent Terminal Elimination Half-life (t1/2el)

Blood samples for bupivacaine PK analysis were to be obtained from subjects at baseline (prior to bupivacaine HCl administration for nerve block), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days after the beginning of EXPAREL administration

Time frame:
Baseline, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours, and 14 days post-dose
Reported as:
Mean · hours
The Apparent Terminal Elimination Half-life (t1/2el)
hoursBupivacaine FNB + EXPAREL InfiltrationBupivacaine FNB + EXPAREL Infiltration Admixed With Bupivacaine
The Apparent Terminal Elimination Half-life (t1/2el)25.9 ± 8.0222 ± NA

Adverse events

Collected over Adverse events were to be monitored from the time the informed consent form was signed through Day 14 post-dose.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bupivacaine FNB + EXPAREL Infiltration0/16 (0%)0/16 (0%)1/16 (6.3%)
Bupivacaine FNB + EXPAREL Infiltration Admixed With Bupivacaine0/7 (0%)0/7 (0%)0/7 (0%)
Most frequent other events
Most frequent other events
EventBupivacaine FNB + EXPAREL InfiltrationBupivacaine FNB + EXPAREL Infiltration Admixed With Bupivacaine
DyspnoeaRespiratory, thoracic and mediastinal disorders1/160/7
HypercapniaRespiratory, thoracic and mediastinal disorders1/160/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Bupivacaine FNB + EXPAREL InfiltrationBupivacaine FNB + EXPAREL Infiltration Admixed With BupivacaineTotal
Mean67.1 ± 8.6159.7 ± 7.0464.9 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Bupivacaine FNB + EXPAREL InfiltrationBupivacaine FNB + EXPAREL Infiltration Admixed With BupivacaineTotal
Female9413
Male7310
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bupivacaine FNB + EXPAREL InfiltrationBupivacaine FNB + EXPAREL Infiltration Admixed With BupivacaineTotal
Hispanic or Latino303
Not Hispanic or Latino13720
Unknown or Not Reported0.00
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bupivacaine FNB + EXPAREL InfiltrationBupivacaine FNB + EXPAREL Infiltration Admixed With BupivacaineTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American112
White15621
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Bupivacaine FNB + EXPAREL InfiltrationBupivacaine FNB + EXPAREL Infiltration Admixed With BupivacaineTotal
United States16723
08

Study locations

1 site
  • Research Concepts, GP, LLC
    Houston, Texas 77054, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2020, 5 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2014
First posted
Oct 2, 2014
Start
Sep 2014
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Nov 24, 2020
Last update
Mar 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02255500
Responsible party
Sponsor
First posted
Oct 2, 2014
Start date
Sep 2014
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Nov 24, 2020
Last update
Mar 8, 2021

Study contacts

David Leiman, MD
principal investigator · Research Concepts, GP, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Liposomal Bupivacaine

Start the discussion